PO.CL01.13 · 临床研究
识别胶质母细胞瘤浸润边缘细胞的分子特征作为肿瘤侵袭和复发的驱动因素
Identifying the molecular signature of infiltrating edge cells in glioblastoma as drivers of tumour invasion and recurrence
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
胶质母细胞瘤(GBM)是成人中最常见的恶性脑肿瘤。尽管进行了大量研究,在解决GBM复发的根源方面仍未取得显著进展,许多罹患这一毁灭性疾病的患者预后仍然不佳。我们对GBM异质性的认识大多局限于可手术切除的肿瘤核心,而由于瘤周病变中存在正常功能性脑组织,对浸润边缘处肿瘤细胞的功能表征在很大程度上仍难以捉摸。边缘来源的细胞表现出更强的浸润性扩张能力,是治疗失败和肿瘤复发的主要驱动因素,使其成为新型治疗方法的作用靶点。在本研究中,我们提出了一项首创性的GBM整合空间研究,结合两种互补的空间组学模态——高清空间转录组学(ST - Visium HD)和空间蛋白质组学(SP - COMET),以实现对侵袭性肿瘤边缘原位的全面形态学、转录组学和蛋白质组学表征。这一多模态空间框架能够解析GBM外周的复杂分子景观,并识别边缘来源恶性细胞群体特异性的可成药生物标志物。通过将病理注释的H&E图像与高分辨率空间基因表达相整合,我们勾勒出组织结构模式,并捕获了跨越肿瘤-脑界面的连续基因表达梯度。使用NicheCompass,我们剖析了组织层级并对GBM浸润区室内的细胞过程进行空间定位。通过无监督表型分析,我们识别出顶部空间可变基因和活跃基因程序,揭示出提示肿瘤细胞劫持神经元通路的模块。这些发现与先前描述的胶质瘤-神经元突触耦合及神经突样肿瘤微管形成机制相一致,与肿瘤边缘处OPC样和NPC样细胞状态的富集相符。作为对转录组层面的补充,SP用于指导ST分析的单细胞分割、基于经典表型标志物推断细胞类型,并通过蛋白质水平分析表征细胞状态和功能。这种双模态方法能够对高度侵袭性的边缘细胞群体及其功能状态进行精确的空间映射。通过整合多个空间组学层面,我们的研究提供了对GBM侵袭前所未有的多模态视角,并识别出区分恶性边缘来源细胞的新型、空间定义的生物标志物。这些发现具有作为诊断和预后工具的潜在转化价值,能够早期评估治疗应答,并促进旨在减缓GBM进展和复发的个性化治疗策略。
查看英文原文 English abstract
Glioblastoma (GBM) is the most common malignant brain tumor in adults. Despite extensive research, there haven't been remarkable gains in resolving the seeds of GBM recurrence, and the outcomes for many patients suffering from this devastating disease remain poor. Our knowledge on GBM heterogeneity is mostly restricted to the surgically resectable tumor core, while functional characterization of tumor cells at the infiltrating edge remains largely elusive due to the presence of normal functional brain tissue in the peritumoral lesion. Edge-derived cells exhibit larger capacity for infiltrative expansion and are the main drivers of treatment failure and tumor recurrence, making them action targets for novel treatment approaches.In this study, we present a first-of-its-kind integrative spatial investigation of GBM, combining two complementary spatial omics modalities high-definition spatial transcriptomics (ST - Visium HD) and spatial proteomics (SP - COMET) to achieve a comprehensive morphological, transcriptomic, and proteomic characterization of invasive tumor edge in situ. This multimodal spatial framework enabled to resolve the complex molecular landscape of the GBM periphery and to identify druggable biomarkers specific to edge-derived malignant cell populations.By integrating pathologically annotated H&E images with high-resolution spatial gene expression, we delineated patterns of tissue architecture and captured continuous gradients of gene expression across tumor-brain interface. Using NicheCompass, we dissected tissue hierarchies and spatially localized cellular processes within the infiltrative compartment of GBM. Through unsupervised phenotyping, we identified top spatially variable genes and active gene programs, revealing modules indicative of tumor cell hijacking of neuronal pathways. These findings align with previously described mechanisms of glioma-neuron synaptic coupling and formation of neurite-like tumor microtubes, consistent with enrichment of OPC- and NPC-like cellular states at tumor margin.Complementing the transcriptomic layer, SP was used to guide single-cell segmentation for ST analysis, infer cell types based on canonical phenotypic markers, and characterize cell state and function through protein-level profiling. This dual-modality approach allowed for precise spatial mapping of highly invasive edge cell populations and their functional states.By integrating multiple spatial omic layers, our study provides an unprecedented multimodal view of GBM invasion and identifies novel, spatially defined biomarkers that distinguish malignant edge-derived cells. These findings hold potential translational value as diagnostic and prognostic tools, enabling early assessment of treatment response and facilitating personalized therapeutic strategies aimed at mitigating GBM progression and recurrence.
利益披露 Disclosure
A. Ivanova, None.
S. Ayyadhury,
CTO Employment, Astraea Bio.
Panoramics - A Vision INC Employment, CEO, Founder.
Y. Ma, None..
X. Gui, None..
A. V. Basi, None.
T. J. Pugh,
AstraZeneca ), Other, TJP has provided consultation for AstraZeneca and receives research support (institutional) from AstraZeneca..
Chrysalis Biomedical Advisors Other, TJP has provided consultation for Chrysalis Biomedical Advisors.
Merck Other, TJP has provided consultation for Merck.
Roche/Genentech ), TJP receives research support (institutional) from Roche/Genentech.
UHN Patent, TJP is an inventor on patents of the CapIG-seq and CapTCR-seq methods held by the University Health Network..
D. G. Munoz, None..
S. Cho, None.
T. Oyewale,
Ariadne.ai Employment.
L. Schütz,
Ariadne.ai CCO Employment.
C. I. Ene, None..
J. K. Burks, None.